Synthesis and cytotoxic activity evaluation of novel arylpiperazine derivatives on human prostate cancer cell lines

Molecules

Volumn 19, Issue 8, 2014, Pages 12048-12064

  Chen, Hong ^a   Liang, Xue ^a   Xu, Fang ^a   Xu, Bingbing ^a   He, Xuelan ^a   Huang, Biyun ^a   Yuan, Mu ^a  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Arylpiperazine derivatives; CCK 8; Cytotoxic activity; Structure activity relationship; Synthesis

Indexed keywords

PIPERAZINE; PIPERAZINE DERIVATIVE;

CELL PROLIFERATION; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; HUMAN; MALE; PATHOLOGY; PROSTATIC NEOPLASMS; STRUCTURE ACTIVITY RELATION; SYNTHESIS; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MALE; PIPERAZINES; PROSTATIC NEOPLASMS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84906668069     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules190812048     Document Type: Article

References (49)

1. Greenlee, R.T.; Murray, T.; Hill-Harmon, M.B.; Thun, M.J. Cancer statistics, 2001. CA: Cancer J. Clin. 2001, 51, 15-36.
2. Quinn, M.; Babb, P. Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part I: International comparisons. BJU Int. 2002, 90, 162-173.
3. Gronberg, H. Prostate cancer epidemiology. Lancet 2003, 361, 859-864.
4. American Cancer Society. Cancer Facts & Figures 2003; American Cancer Society: Atlanta, GA, USA, 2003.
5. Steinberg, G.D.; Carter, B.S.; Beaty, T.H.; Childs, B.; Walsh, P.C. Family history and the risk of prostate cancer. Prostate 1990, 17, 337-347.
6. Bratt, O. Hereditary prostate cancer: Clinical aspects. J. Urol. 2002, 168, 906-913.
7. Whittemore, A.; Kolonel, L.N.; Wu, A.H.; John, E.M.; Gallagher, R.P.; Howe, G.R.; Burch, J.D.; Hankin, J.; Dreon, D.M.; West, D.W. Prostate cancer in relation to diet, physical activity, and body size in blacks, whites, and Asians in the United States and Canada. J. Natl. Cancer Inst. 1995, 87, 652-661.
8. Isaacs, J.T. Role of androgens in prostatic cancer. Vitam. Horm. 1994, 49, 433-502.
9. Frydenberg, M.; Stricker, P.D.; Kaye, K.W. Prostate cancer diagnosis and management. Lancet 1997, 349, 1681-1687.
10. Akduman, B.; Crawford, E.D. The management of high risk prostate cancer. J. Urol. 2003, 169, 1993-1998.
11. Huggins, C.; Hodges, C.V. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J. Urol. 2002, 167, 948-951.
12. Beedassy, A.; Cardi, G. Chemotherapy in advanced prostate cancer. Semin. Oncol. 1999, 26, 428-438.
13. Denmeade, S.R.; Lin, X.S.; Isaacs, J.T. Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate 1996, 28, 251-265.
14. Tang, D.G.; Porter, A.T. Target to apoptosis: A hopeful weapon for prostate cancer. Prostate 1997, 32, 284-293.
15. Craft, N.; Chhor, C.; Tran, C.; Belldegrun, A.; DeKernion, J.; Witte, O.N.; Said, J.; Reiter, R.E.; Sawyers, C.L. Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process. Cancer Res. 1999, 59, 5030-5036.
16. Szkaradek, N.; Rapacz, A.; Pytka, K.; Filipek, B.; Siwek, A.; Cegła, M.; Marona, H. Synthesis and preliminary evaluation of pharmacological properties of some piperazine derivatives of xanthone. Bioorg. Med. Chem. 2013, 21, 514-522.
17. Cecchetti, V; Fravolini, A.; Schiaffella, F.; Tabarrini, O.; Bruni, G.; Segret, G. O-Chlorobenzenesulfonamidic derivatives of (aryloxy)propanolamines as beta-blocking/diuretic agents. J. Med. Chem. 1993, 36, 157-161.
18. Walsh, D.A.; Chen, Y.H.; Green, J.B.; Nolan, J.C.; Yannit, J.M. The synthesis and antiallergy activity of 1-(aryloxy)-4-(4-arylpiperazinyl)-2- butanol derivatives. J. Med. Chem. 1990, 33, 1823-1827.
19. Seo, HJ.; Park, E.J.; Kim, M.J.; Kang, S.Y.; Lee, S.H.; Kim, H.J.; Lee, K.N.; Jung, M.E.; Lee, M.; Kim, M.S.; et al. Design and synthesis of novel arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter. J. Med. Chem. 2011, 54, 6305-6318.
20. Kikumoto, R.; Tobe, A.; Fukami, H.; Egawa, M. Synthesis and antianxiety activity of (omega-piperazinylalkoxy)indan derivatives. J. Med. Chem. 1983, 26, 246-250.
21. Jaen, J.C.; Wise, L.D.; Heffner, T.G.; Pugsley, T.A.; Meltzed, L.T. Dopamine autoreceptor agonists as potential antipsychotics. 1. (Aminoalkoxy)anilines. J. Med. Chem. 1988, 31, 1621-1625.
22. Cross, R.M.; Namelikonda, N.K.; Mutka, T.S.; Luong, L.; Kyle, D.E.; Manetsch, R. Synthesis, antimalarial activity, and structure-activity relationship of 7-(2-phenoxyethoxy)-4(1H)-quinolones. J. Med. Chem. 2011, 54, 8321-8327.
23. Clarkson, C.; Musonda, C.C.; Chibale, K.; Campbella, W.E.; Smitha, P. Synthesis of totarol amino alcohol derivatives and their antiplasmodial activity and cytotoxicity. Bioorg. Med. Chem. 2003, 11, 4417-4422.
24. Leopoldo, M.; Lacivita, E.; Passafiume, E.; Contino, M.; Colabufo, N.A.; Berardi, F.; Perrone, R. 4-[omega-[4-arylpiperazin-1-yl]alkoxy]phenyl)imidazo[1, 2-a]pyridine derivatives: Fluorescent high-affinity dopamine D3 receptor ligands as potential probes for receptor visualization. J. Med. Chem. 2007, 50, 5043-5047.
25. 2 receptor agonists. J. Med. Chem. 2012, 55, 7141-7153.
26. Romeiro, L.A.; da Silva Ferreira, M.; da Silva, L.L.; Castro, H.C.; Miranda, A.L.; Silva, C.L.; Noël, F.; Nascimento, J.B.; Araújo, C.V.; Tibiriçá, E.; et al. Discovery of LASSBio-772, a 1,3-benzodioxole N-phenylpiperazine derivative with potent alpha 1A/D-adrenergic receptor blocking properties. Eur. J. Med. Chem. 2011, 46, 3000-3012.
27. Baran, M.; Kepczynska, E.; Zylewski, M.; Siwek, A.; Bednarski, M.; Cegla, M.T. Studies on novel pyridine and 2-pyridone derivatives of N-arylpiperazine as α-adrenoceptor ligands. Med. Chem. 2014, 10, 144-153.
28. Dellabella, M.; Milanese, G.; Muzzonigro, G. Efficacy of tamsulosin in the medical management of juxtavesical ureteral stones. J. Urol. 2003, 170, 2202-2205.
29. Morita, T.; Wada, I.; Saeki, H.; Tsuchida, S.; Weiss, R.M. Ureteral urine transport: Changes in bolus volume, peristaltic frequency, intraluminal pressure and volume of flow resulting from autonomic drugs. J. Urol. 1987, 137, 132-135.
30. Takei, R.; Ikegaki, I.; Shibata, K.; Tsujimoto, G.; Asano, T. Naftopidil, a novel alpha1-adrenoceptor antagonist, displays selective inhibition of canine prostatic pressure and high affinity binding to cloned human alpha1-adrenoceptors. Jpn. J. Pharmacol. 1999, 79, 447-454.
31. Nishino, Y.; Masue, T.; Miwa, K.; Takahashi, Y.; Ishihara, S.; Deguchi, T. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: A randomized crossover study. BJU Int. 2006, 97, 747-751.
32. Kojima, Y.; Sasaki, S.; Kubota, Y.; Hayase, M.; Hayashi, Y.; Shinoura, H.; Tsujimoto, G.; Kohri, K. Expression of alpha1-adrenoceptor subtype mRNA as a predictor of the efficacy of subtype selective alpha1-adrenoceptor antagonists in the management of benign prostatic hyperplasia. J. Urol. 2008, 179, 1040-1046.
33. Hori, Y.; Ishii, K.; Kanda, H.; Iwamoto, Y.; Nishikawa, K.; Soga, N.; Kise, H.; Arima, K.; Sugimura, Y. Naftopidil, a selective {alpha}1-adrenoceptor antagonist, suppresses human prostate tumor growth by altering interactions between tumor cells and stroma. Cancer Prev. Res (Phila). 2011, 4, 87-96.
34. Kanda, H.; Ishii, K.; Ogura, Y.; Imamura, T.; Kanai, M.; Arima, K.; Sugimura, Y. Naftopidil, a selective alpha-1 adrenoceptor antagonist, inhibits growth of human prostate cancer cells by G1 cell cycle arrest. Int. J. Cancer 2008, 122, 444-451.
35. Gotoh, A.; Nagaya, H.; Kanno, T.; Nishizaki, T. Antitumor action of α(1)-adrenoceptor blockers on human bladder, prostate and renal cancer cells. Pharmacology 2012, 90, 242-246.
36. Masachika, E.; Kanno, T.; Nakano, T.; Gotoh, A.; Nishizaki, T. Naftopidil induces apoptosis in malignant mesothelioma cell lines independently of α1-adrenoceptor blocking. Anticancer Res. 2013, 33, 887-894.
37. Li, S.; Chiu, G.; Pulito, V.L.; Liu, J.; Connolly, P.J.; Middleton, S.A. 1-Arylpiperazinyl-4-cyclohexylamine derived isoindole-1,3-diones as potent and selective alpha-1a/1d adrenergic receptor ligands. Bioorg. Med. Chem. Lett. 2007, 17, 1646-1650.
38. Chiu, G.; Li, S.; Connolly, P.J.; Pulito, V.; Liu, J.; Middleton, S.A. (Arylpiperazinyl)cyclohexylsufonamides: Discovery of alpha(1a/1d)-selective adrenergic receptor antagonists for the treatment of Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms (BPH/LUTS). Bioorg. Med. Chem. Lett. 2007, 17, 3292-3297.
39. Kuo, G.H.; Prouty, C.; Murray, W.V.; Pulito, V.; Jolliffe, L.; Cheung, P.; Varga, S.; Evangelisto, M.; Shaw, C. Design, synthesis and biological evaluation of pyridine-phenylpiperazines: A novel series of potent and selective alpha1a-adrenergic receptor antagonist. Bioorg. Med. Chem. 2000, 8, 2263-2275.
40. Khatuya, H.; Hutchings, R.H.; Kuo, G.H.; Pulito, V.L.; Jolliffe, L.K.; Li, X.; Murray, W.V. Arylpiperazine substituted heterocycles as selective alpha(1a) adrenergic antagonists. Bioorg. Med. Chem. Lett. 2002, 12, 2443-2446.
41. Konkel, M.J.; Wetzel, J.M.; Cahir, M.; Craig, D.A.; Noble, S.A.; Gluchowski, C. Synthesis and structure-activity relationship of fluoro analogues of 8-{2-[4-(4-methoxyphenyl)piperazin-1yl]ethyl}-8-azaspiro[4.5]decane-7,9- dione as selective alpha(1d)-adrenergic receptor antagonists. J. Med. Chem. 2005, 48, 3076-3079.
42. 1- adrenoceptor subtypes. Eur. J. Med. Chem. 2011, 46, 2676-2690.
43. Huang, J.J.; Huang, Y.J.; Zhu, L.; Yuan, M. Design, synthesis and α1-adrenoreceptor blocking activity of new arylpiperazines containing acetophenone substituents. Pharmazie 2014, 69, 1-7.
44. Liu, X.W.; Zhang, Y.Y.; Yuan, M.; Sun, Y.X. Determination of naftopidil enantiomers in rat plasma using chiral solid phases and pre-column derivatization high-performance liquid chromatography. J. Chromatogr. B 2012, 907, 140-145.
45. Zhao, X.; Chen, M.S.; Huang, B.Y.; Ji, H.; Yuan, M. Comparative Molecular Field Analysis (CoMFA) and Comparative Molecular Similarity Indices Analysis (CoMSIA) studies on α(1A)-adrenergic receptor antagonists based on pharmacophore molecular alignment. Int. J. Mol. Sci. 2011, 12, 7022-7037.
46. Zhao, X.; Yuan, M.; Huang, B.Y.; Ji, H.; Zhu, L. Ligand-based pharmacophore model of N-Aryl and N-Heteroaryl piperazine alpha 1A-adrenoceptors antagonists using GALAHAD. J. Mol. Graph. Model. 2010, 29, 126-136.
47. Kaspers, G.J.; Veerman, A.J.; Pieters, R.; van Zantwijk, C.H.; Smets, L.A.; van Wering, E.R.; van der Does-Van Den Berg, A. In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia. Blood 1997, 90, 2723-2729.
48. Kaspers, G.J.; Pieters, R.; van Zantwijk, C.H.; VanWering, E.R.; van der Does-Van Den Berg, A.; Veerman, A.J. Prednisolone resistance in childhood acute lymphoblastic leukemia: Vitro-vivo correlations and cross-resistance to other drugs. Blood 1998, 92, 259-266.
49. Ding, J.; Huang, S.L.; Wu, S.Q.; Zhao, Y.J.; Liang, L.H.; Yan, M.X.; Ge, C.; Yao, J.; Chen, T.Y.; Wan, D.F.; et al. Gain of miR-151 on chromosome 8q24.3 facilitates tumour cell migration and spreading through downregulating RhoGDIA. Nat. Cell Biol. 2010, 12, 390-399.